

HuaMedicine
华领医药

“ ”

1 2

3 4 5


6 7 8


a

b

Copyright © Hua Medicine 2023


H
H M





7030


299.6%

Q1 4

Q3 8

Copyright © Hua Medicine 2023


H
H M



GLP-1

DREAM SEED 2

65%


52

GK

GK


TIR

IGT




Source: Chen L, Zhang JY et al. Nature Communications , A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity 2023, 3 1405.

Copyright © Hua Medicine 2023






GLP-1



GLP-1

Copyright © Hua Medicine 2023


Copyright © Hua Medicine 2023




Copyright © Hua Medicine 2023

Goto-Kakizaki


26 GK






Copyright © Hua Medicine 2023

HFD /






19

19 10 18 38

45

Copyright © Hua Medicine 2024


24



TIR

TIR 46 83.7%

TIR




[redacted]

TIR

Diabetes Obes Metab.2023 Jun 29. doi: 10.1111/dom.15179

Copyright © Hua Medicine 2024


H
H M



Copyright © Hua Medicine 2023


GKA

1

β


GKA


β




Copyright © Hua Medicine 2023

4.7 15





Copyright © Hua Medicine 2023



GLP-1RA

AI

Copyright © Hua Medicine 2023

2023

Q4


Copyright © Hua Medicine 2023



H M
A

____ 2023 70.3

® 2023 6 30 ® 212
000 70.3 2022 299.6%
2023 6 30 265,000 ® 87.9

____ 2023 44.0 62.6%
43.7% 18.9%





Copyright © Hua Medicine 2023

_____ 2023 38.6

2022 21.4 17.2 2023
21.7 6.2
10.7

_____ 2023 90.1 2022 14.5

_____ 2023 / Ņ Ƒ

Copyright © Hua Medicine 2023

_____ 2022 6 30 72.3 1.3 2023 6 30
71.0

- Dorzagliatin 2022 6 30 0.8 3.2 2023
6 30 4.0 2023 2022

- 2022 6 30 9.0 2.9 2023 6 30

)D2'¶) I#-õ+9ü3hR9÷H/ UgFj`&¦r”FVž"ß(ïŸÃ2 Vt “Sde^Ð

2023

Copyright © Hu Medic 2023

Copyright © Hua Medicine 2023



